Clinical Trials Directory

Trials / Completed

CompletedNCT04953286

Ocular Surface Metabolo-lipidomics in Lateral Amyotrophic Sclerosis

Tear Fluid and Ocular Surface Metabolomics and Lipidomics in Lateral Amyotrophic Sclerosis: a Prospective Comparative Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
55 (actual)
Sponsor
University Hospital, Tours · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Accepted

Summary

Amyotrophic Lateral Sclerosis (ALS) is the most common neurodegenerative disease affecting the motor neuron. Currently, there is no diagnostic test and no examination that can predict the evolution of this pathology. The search for diagnostic and prognostic biomarkers is therefore essential for a better understanding of the pathophysiology of ALS, which remains poorly understood, and also for better clinical management. The ocular surface, made up of liquid elements, tears, and cells, is an accessible anatomical-physiological entity that has demonstrated its usefulness in the identification of biomarkers in neurodegenerative diseases such as Parkinson's or Alzheimer's. To date, no study has explored the ocular surface as a biomarker in ALS

Conditions

Interventions

TypeNameDescription
OTHERMeasure of visual acuityETDRS and Parinaud scale
OTHERInterferometryNon-contact exam measuring N.I.B.U.T (Non-invasive break-up time), quantitative and qualitative evaluation of the meibomian glands and quantitative evaluation of the tear meniscus
OTHERSamples of basal tearsCollection of basal tears without instillation of anesthetic with a Schirmer strip for 5 minutes and by microcapillary
OTHERCentral corneal sensitivityCentral corneal sensitivity using a Cochet-Bonnet esthesiometer (Luneau©)
OTHERSlit lamp examination and undilated fundusSlit lamp examination and undilated fundus
OTHERConjunctival impressionConjunctival impression with anesthetic instillation
OTHEREvaluation of the corneal innervationContact corneal confocal microscopy

Timeline

Start date
2021-09-17
Primary completion
2023-09-30
Completion
2023-09-30
First posted
2021-07-07
Last updated
2025-12-22

Locations

3 sites across 1 country: France

Source: ClinicalTrials.gov record NCT04953286. Inclusion in this directory is not an endorsement.